Skip to main content
Midas Edge

Sana Biotechnology, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

SANA$2.43-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance as of December 31, 2025266,732$27$2,009,845$28$(1,849,016)$160,884
Fees incurred related to issuance of common stock--(125)--(125)
Exercise of pre-funded warrants2,192-----
Vesting of restricted stock864-----
Exercise of stock options29-59--59
Stock-based compensation expense--5,662--5,662
Unrealized loss on marketable securities, net---(30)-(30)
Net loss----(47,210)(47,210)
Balance as of March 31, 2026269,817$27$2,015,441$(2)$(1,896,226)$119,240
Issuance of common stock, net of issuance costs of $1,25229,115389,749--89,752
Issuance of common stock allocated to stock purchase option--3,688--3,688
Vesting of restricted stock230-----
Exercise of stock options29-59--59
Issuance of common stock related to employee stock purchase plan115-186--186
Stock-based compensation expense--5,342--5,342
Unrealized loss on marketable securities, net---(64)-(64)
Net loss----(63,635)(63,635)
Balance as of June 30, 2026299,306$30$2,114,465$(66)$(1,959,861)$154,568
Fees incurred related to issuance of common stock--(9)--(9)
Vesting of restricted stock156-----
Exercise of stock options59-117--117
Stock-based compensation expense--5,325--5,325
Unrealized loss on marketable securities, net---(38)-(38)
Net income----20,40120,401
Balance as of September 30, 2026299,521$30$2,119,898$(104)$(1,939,460)$180,364
Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balance as of December 31, 2024223,923$22$1,855,318$14$(1,604,850)$250,504
Fees incurred related to issuance of common stock--(171)--(171)
Vesting of restricted stock960-----
Exercise of stock options58011,126--1,127
Stock-based compensation expense--7,022--7,022
Unrealized loss on marketable securities, net---(14)-(14)
Net loss----(49,389)(49,389)
Balance as of March 31, 2025225,463$23$1,863,295$-$(1,654,239)$209,079
Issuance of common stock from at the market offering, net of issuance costs of $174170-315--315
Exercise of pre-funded warrants4,445-----
Vesting of restricted stock203-----
Exercise of stock options102-148--148
Issuance of common stock related to employee stock purchase plan127-185--185
Stock-based compensation expense--6,629--6,629
Net loss----(93,800)(93,800)
Balance as of June 30, 2025230,510$23$1,870,572$-$(1,748,039)$122,556
Issuance of common stock from at the market offering, net of issuance costs of $8867,272128,624--28,625
Issuance of common stock from common stock financings, net of issuance costs of $5,62524,254280,623--80,625
Vesting of restricted stock153-----
Exercise of stock options75-158--158
Stock-based compensation expense--5,475--5,475
Unrealized gain on marketable securities, net---21-21
Net loss----(42,152)(42,152)
Balance as of September 30, 2025262,264$26$1,985,452$21$(1,790,191)$195,308
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.